Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial

被引：0
|
作者：
Jiang, Y-F. [1 ]
Bei, W-X. [1 ]
Wang, L. [2 ]
Xu, C. [2 ]
Lu, N. [3 ]
Liang, H. [4 ]
Ke, L-R. [3 ]
Ye, Y-F. [5 ]
Fang, T. [1 ]
He, S. [6 ]
Dong, S-H. [1 ]
Liu, Q. [1 ]
Zhang, C. [1 ]
Xia, W. [1 ]
Zhao, C. [1 ]
Xie, C. [7 ]
Liu, G. [8 ]
Xiang, Y-Q. [1 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, Dept Radiol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[5] Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Radiat Oncol, Guang Zhou, Peoples R China
[7] NCI, Thorac & GI Malignancies Branch, Bethesda, MD USA
[8] Sun Yat Sen Univ, Radiotherapy Dept, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
893P
引用
收藏
页码：S633 / S634
页数：2
相关论文
共 50 条
  • [41] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study (POLARIS-03)
    Sheng, Xinan
    Chen, Haige
    Hu, Bin
    Yao, Xudong
    Liu, Ziling
    Yao, Xin
    Guo, Hongqian
    Hu, Yi
    Ji, Zhigang
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    Wu, Jin
    Zhou, Fang-Jian
    He, Zhisong
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
    Hua, Yijun
    You, Rui
    Wang, Zhiqiang
    Huang, Peiyu
    Lin, Mei
    Ouyang, Yanfeng
    Xie, Yulong
    Zou, Xiong
    Liu, Youping
    Duan, Chongyang
    Liu, Yonglong
    Gu, Chenmei
    Liu, Rongzeng
    Yang, Qi
    Jiang, Rou
    Zhang, Mengxia
    Ding, Xi
    Chen, Siyuan
    Lin, Chao
    Sun, Rui
    Chen, Mingyuan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [43] Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial
    Zhu, X.
    Sun, L.
    Song, N.
    Sun, F.
    Yang, J.
    Duan, L.
    Zhao, D.
    He, W.
    Luo, J.
    Zhang, H.
    Wu, C.
    Zhu, Y.
    Zhang, P.
    Jiang, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S942 - S942
  • [44] Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy
    Holmes, Zachary
    Courtney, Ashling
    Hiong, Alison
    BMJ CASE REPORTS, 2022, 15 (08)
  • [45] A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors.
    Markman, Ben
    Hsieh, Amy Hsin-Chieh
    Coward, Jermaine
    Carlino, Matteo S.
    Frentzas, Sophia
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the AK104-IIT-003 study
    Tang, Jie
    Tian, Wenfang
    Huang, Si
    Yang, Jun
    Yang, Hongying
    Zhang, Jieqing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] A novel trispecific antibody HC010 targeting PD-1/CTLA-4/VEGF for the potential treatment in anti-PD-1 antibody resistant NSCLC patients
    Jiang, Diandong
    Xi, Yue
    Xu, Chen
    Wang, Xingding
    Yin, Qiaoshan
    Li, Zhaohui
    Yang, Teddy
    CANCER RESEARCH, 2024, 84 (06)
  • [48] A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF INCAGN01876 (ANTI-GITR AGONIST) IN COMBINATION WITH RETIFANLIMAB (ANTI-PD-1) IN RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Leidner, Rom
    Haddad, Robert
    Bourayou, Nawel
    Ioannidis, Sonia
    Zhou, Feng
    Dong, Zhiwan
    Cohen, Ezra
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A707 - A707
  • [49] Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy
    Wilky, B. A.
    Kumthekar, P.
    Wesolowski, R.
    Hwang, J. J.
    Park, S. I.
    Yuan, G.
    Dupont, C. D.
    Lim, M.
    Shebanova, O.
    Cuillerot, J-M.
    Dow, E.
    Ortuzar, W.
    Raizer, J. J.
    Drouin, E.
    Wilson, N.
    Gonzalez, A. M.
    Goldberg, J. M.
    Buell, J. S.
    Stein, R. B.
    Youssoufian, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Preliminary efficacy and safety results of a prospective phase II trial
    Xing, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S822 - S822
12345